

# UnitedHealthcare Medicare Advantage Reimbursement Policy Update Bulletin: June 2022

Updated		
Policy Title	Effective Date	Summary of Changes
Molecular Pathology Policy Professional and Facility	06/01/2022	<p>The policy has been updated to provide further details of payment policies associated with molecular pathology claims:</p> <ul style="list-style-type: none"> <li>• Reimbursement Guidelines section revised to include guidelines for Multiple Gene Testing with code table references for Tier 1 and Tier 2 Molecular Pathology codes, Genomic Sequencing Procedures and Other Molecular Multianalyte Assays.</li> <li>• Definitions section revised to include definitions for Genomic Sequencing Procedures and Other Molecular Multianalyte Assays and Proprietary Laboratory Analysis (PLA) Codes.</li> <li>• Questions and Answers (Q&amp;A) section updated to include additional Q&amp;A specific to Multiple Gene Testing.</li> </ul>

Published reimbursement policies are intended to ensure reimbursement based on the code or codes that correctly describe the health care services provided. UnitedHealthcare reimbursement policies may use Current Procedural Terminology (CPT®\*), Centers for Medicare and Medicaid Services (CMS) or other coding guidelines. References to CPT or other sources are for definitional purposes only and do not imply any right to reimbursement

**Note:** The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member’s benefit plan and any applicable federal or state regulatory requirements.



The complete library of UnitedHealthcare Medicare Advantage Reimbursement Policies is available [UHCprovider.com](https://UHCprovider.com) > Policies and Protocols > Medicare-Advantage-Policies > [Medicare-Advantage-Reimbursement Policies](#).